Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald J Dal Pan

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Pharmacoepidemiology and Drug Safety|October 29, 2010
Commentary on "Secondary use of electronic health record data: spontaneous triggered adverse drug event reporting" by Linder et alGerald J Dal Pan
Medical Care|May 15, 2012
Communicating the risks of medicines: time to move forwardGerald J Dal Pan
JAMA Internal Medicine|April 30, 2019
Gauging the Effectiveness of Medicines Safety Communications From Global Regulatory AgenciesGerald J Dal Pan
Clinical Pharmacology and Therapeutics|April 9, 2019
Real-World Data, Advanced Analytics, and the Evolution of Postmarket Drug Safety SurveillanceGerald J Dal Pan
Clinical Pharmacology and Therapeutics|October 26, 2021
The Use of Real-World Data to Assess the Impact of Safety-Related Regulatory InterventionsGerald J Dal Pan
Drug Safety|November 23, 2013
Ongoing challenges in pharmacovigilanceGerald J Dal Pan
Neurology. Clinical Practice|February 15, 2018
The US Food and Drug Administration, neurologists, and drug development and regulationGerald J Dal Pan
Pharmacoepidemiology and Drug Safety|May 11, 2013
Commentary on "The effectiveness of varenicline medication guide for conveying safety information to patients: a REMS assessment survey" by Enger et alGerald J Dal Pan
Archives of Internal Medicine|November 16, 2011
Balancing transparency and uncertaintyGerald J Dal Pan, Robert Temple
Drug Safety|May 18, 2019
The Impact of Litigation-Associated Reports on Signal Identification in the US FDA's Adverse Event Reporting SystemMonica A Muñoz, Gerald J Dal Pan
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Pharmacoepidemiology and Drug Safety|October 29, 2010
Commentary on "Secondary use of electronic health record data: spontaneous triggered adverse drug event reporting" by Linder et alGerald J Dal Pan
Medical Care|May 15, 2012
Communicating the risks of medicines: time to move forwardGerald J Dal Pan
JAMA Internal Medicine|April 30, 2019
Gauging the Effectiveness of Medicines Safety Communications From Global Regulatory AgenciesGerald J Dal Pan
Clinical Pharmacology and Therapeutics|April 9, 2019
Real-World Data, Advanced Analytics, and the Evolution of Postmarket Drug Safety SurveillanceGerald J Dal Pan
Clinical Pharmacology and Therapeutics|October 26, 2021
The Use of Real-World Data to Assess the Impact of Safety-Related Regulatory InterventionsGerald J Dal Pan
Drug Safety|November 23, 2013
Ongoing challenges in pharmacovigilanceGerald J Dal Pan
Neurology. Clinical Practice|February 15, 2018
The US Food and Drug Administration, neurologists, and drug development and regulationGerald J Dal Pan
Pharmacoepidemiology and Drug Safety|May 11, 2013
Commentary on "The effectiveness of varenicline medication guide for conveying safety information to patients: a REMS assessment survey" by Enger et alGerald J Dal Pan
Archives of Internal Medicine|November 16, 2011
Balancing transparency and uncertaintyGerald J Dal Pan, Robert Temple
Drug Safety|May 18, 2019
The Impact of Litigation-Associated Reports on Signal Identification in the US FDA's Adverse Event Reporting SystemMonica A Muñoz, Gerald J Dal Pan
Pageof 7